Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Netarsudil/Latanoprost for Pseudophakic Bullous Keratopathy in Glaucoma
NCT06960629Phase 3Completed
- Sponsor
- Dubrava University Hospital
- Start
- May 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netarsudil and latanoprost ophthalmic solution 0.005% (TearClear TC-002) in pseudophakic bullous keratopathy (PBK) (2 arms), sponsored by Dubrava University Hospital. Primary endpoint: Visual Acuity at 12 weeks. Started May 2025; status: completed.
02
Drugs
netarsudillatanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
pseudophakic bullous keratopathy (PBK)
Beyond the preview
Go deeper on NCT06960629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960629.